A novel and sensitive chemiluminescence (CL) method for the determination of indapamide coupled with flow-injection analysis (FIA) technique is developed in this paper. It is based on the inhibition effect of the studied drug on the chemiluminescence emission of luminol-potassium ferricyanide system. Under the optimum conditions, the decreased CL intensity is proportional with the concentration of indapamide in the range of 1 x 10(-8) to 1.0 x 10(-6) g ml(-1). The detection limit is 3.4 x 10(-9) g ml(-1) (3sigma). A complete analysis could be performed in 45 s including washing and sampling, giving a throughout of about 90 h(-1). The relative standard deviation (R.S.D.) for 11 parallel measurements of 1.0 x 10(-7) g ml(-1) indapamide is 3.0%. The proposed method has been applied for the determination of indapamide in its pharmaceutical formulations. The results obtained compared well with those by an official method. The possible inhibition mechanism of indapamide on luminol-potassium ferricyanide CL system was discussed briefly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0731-7085(03)00642-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of combination of zofenopril and different diuretics on regression of myocardial reperfusion injury and oxidative status in spontaneously hypertensive rats.
Mol Cell Biochem
January 2025
Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
Article Synopsis
- The study investigated the effects of ACE inhibitors and diuretics on heart damage from ischemia-reperfusion in hypertensive rats, showing significant blood pressure reduction and improved heart function.
- After four weeks of treatment, a combination of drugs decreased left ventricular hypertrophy and increased ejection fraction, but also indicated potential pro-oxidative effects.
- Pathological analysis revealed no significant changes in heart and kidney tissues, and further research is necessary to explore the long-term effects of these medications.
Study of the Acidic, Basic, and Thermal Degradation Kinetics of Three Antihypertensive Drugs-Individually and in Combination.
Pharmaceutics
November 2024
Faculty of Physical Chemistry, University of Belgrade, Studentski Trg 12-16, 11158 Belgrade, Serbia.
Background/objectives: The importance of fixed-dose combinations (FDCs) for the treatment of hypertension is well established. However, from a stability perspective, FDCs present a challenge since the degradation of one active pharmaceutical ingredient (API) can be affected by the presence of another API. The aim of this study was to compare the degradation behaviors and evaluate the degradation kinetics of three antihypertensive drugs, perindopril tert-butylamine (PER), amlodipine besylate (AML), and indapamide (IND).
View Article and Find Full Text PDFTreatment optimisation for blood pressure with single-pill combinations in India (TOPSPIN) - Protocol design and baseline characteristics.
Int J Cardiol Cardiovasc Risk Prev
December 2024
Imperial Clinical Trials Unit, Imperial College London, 1st Floor, Stadium House, 68 Wood Lane, London, W12 7RH, UK, United Kingdom.
Background: The burden of over 300 million individuals living with hypertension in India is increasing steadily. Most current guidelines recommend initial combination therapy for effective blood pressure (BP) control. However, there is no randomised evidence to inform which combinations to use in the South Asian population, who account for over one-quarter of the world's population.
View Article and Find Full Text PDFReal-World Evidence of Indapamide-Induced Rhabdomyolysis: A Retrospective Analysis of Electronic Health Records.
Pharmacoepidemiol Drug Saf
November 2024
Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
Purpose: Previous research and pharmacovigilance monitoring activities have suggested a potential association between indapamide use and rhabdomyolysis. This study aims to investigate the potential causal relationship between the use of indapamide and rhabdomyolysis.
Methods: A case-control study conducted using electronic health records data, between July 1, 2016 and December 31, 2022.
Background: Arterial hypertension (AH) remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with AH who are on monotherapy cannot achieve blood pressure (BP) targets, and therefore all quidelines for the management of AH have recently recommended prescribing combination therapy (PCT). In real clinical practice (RCP), there remains significant uncertainty in the effectiveness and rationality of therapy, despite the wide availability of antihypertensive drugs (AHD) and the presence of recommendations for a stepwise approach to prescribing combinations of specific groups of AHD in different clinical situations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!